Taysha Gene Therapies Research and Development Expenses 2020-2024 | TSHA
Taysha Gene Therapies research and development expenses from 2020 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Taysha Gene Therapies Annual Research and Development Expenses
(Millions of US $) |
| 2023 |
$57 |
| 2022 |
$91 |
| 2021 |
$132 |
| 2020 |
$32 |
| 2019 |
$0 |
Taysha Gene Therapies Quarterly Research and Development Expenses
(Millions of US $) |
| 2024-06-30 |
$15 |
| 2024-03-31 |
$21 |
| 2023-12-31 |
$13 |
| 2023-09-30 |
$12 |
| 2023-06-30 |
$20 |
| 2023-03-31 |
$13 |
| 2022-12-31 |
$13 |
| 2022-09-30 |
$17 |
| 2022-06-30 |
$24 |
| 2022-03-31 |
$38 |
| 2021-12-31 |
$38 |
| 2021-09-30 |
$40 |
| 2021-06-30 |
$31 |
| 2021-03-31 |
$24 |
| 2020-12-31 |
$12 |
| 2020-09-30 |
$11 |
| 2020-06-30 |
$3 |
| 2020-03-31 |
$6 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.449B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
